In advance of the oncology conference of the ESMO (European Society for Medical Oncology) in Milan on Monday, Severin Schwan, Chief Executive Officer of Roche Holding AG announced his opinion that the data from the Phase II trial for T-DM1 was “stunning.” T-DM1is in clinical trials for breast cancer. It is the first of a new kind of “armed antibody” that can carry a cell-killing payload into cancer cells. The drug is being developed with partner ImmunoGen. T-DM1’s results were better than than that of Herceptin plus Taxotere. In addition, clinically adverse side effects were lower.
Herceptin, also a Roche drug, and currently has sales of about $5 billion annually.
More details will be released this week.
T-DM1 has advanced to Phase III testing.
For further details about this press information from Reuters please click here.
For products that can help alleviate unpleasant side effects from current breast cancer treatments including radiation and chemotherapy please view our website www.LotsToLiveFor.com